Table of Contents Author Guidelines Submit a Manuscript
Mediators of Inflammation
Volume 2015 (2015), Article ID 841097, 9 pages
http://dx.doi.org/10.1155/2015/841097
Review Article

Epigenetic Regulations of Inflammatory Cyclooxygenase-Derived Prostanoids: Molecular Basis and Pathophysiological Consequences

Faculty of Dental Medicine, University of Monastir, 5000 Monastir, Tunisia

Received 12 January 2015; Accepted 29 March 2015

Academic Editor: Marc Pouliot

Copyright © 2015 Hedi Harizi. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. H. Harizi, J.-B. Corcuff, and N. Gualde, “Arachidonic-acid-derived eicosanoids: roles in biology and immunopathology,” Trends in Molecular Medicine, vol. 14, no. 10, pp. 461–469, 2008. View at Publisher · View at Google Scholar · View at Scopus
  2. S. Narumiya, Y. Sugimoto, and F. Ushikubi, “Prostanoid receptors: structures, properties, and functions,” Physiological Reviews, vol. 79, no. 4, pp. 1193–1226, 1999. View at Google Scholar · View at Scopus
  3. C. D. Funk, “Prostaglandins and leukotrienes: advances in eicosanoid biology,” Science, vol. 294, no. 5548, pp. 1871–1875, 2001. View at Publisher · View at Google Scholar · View at Scopus
  4. S. L. Tilley, T. M. Coffman, and B. H. Koller, “Mixed messages: modulation of inflammation and immune responses by prostaglandins and thromboxanes,” The Journal of Clinical Investigation, vol. 108, no. 1, pp. 15–23, 2001. View at Publisher · View at Google Scholar · View at Scopus
  5. N. Gualde and H. Harizi, “Prostanoids and their receptors that modulate dendritic cell-mediated immunity,” Immunology and Cell Biology, vol. 82, no. 4, pp. 353–360, 2004. View at Publisher · View at Google Scholar · View at Scopus
  6. S. G. Harris, J. Padilla, L. Koumas, D. Ray, and R. P. Phipps, “Prostaglandins as modulators of immunity,” Trends in Immunology, vol. 23, no. 3, pp. 144–150, 2002. View at Publisher · View at Google Scholar · View at Scopus
  7. H. Harizi, C. Grosset, and N. Gualde, “Prostaglandin E2 modulates dendritic cell function via EP2 and EP4 receptor subtypes,” Journal of Leukocyte Biology, vol. 73, no. 6, pp. 756–763, 2003. View at Publisher · View at Google Scholar · View at Scopus
  8. C. Münz, R. M. Steinman, and S.-I. Fujii, “Dendritic cell maturation by innate lymphocytes: coordinated stimulation of innate and adaptive immunity,” Journal of Experimental Medicine, vol. 202, no. 2, pp. 203–207, 2005. View at Publisher · View at Google Scholar · View at Scopus
  9. M. Betz and B. S. Fox, “Prostaglandin E2 inhibits production of Th1 lymphokines but not of Th2 lymphokines,” Journal of Immunology, vol. 146, no. 1, pp. 108–113, 1991. View at Google Scholar · View at Scopus
  10. E. M. Aandahl, W. J. Moretto, P. A. Haslett et al., “Inhibition of antigen-specific T cell proliferation and cytokine production by protein kinase A type I,” Journal of Immunology, vol. 169, no. 2, pp. 802–808, 2002. View at Publisher · View at Google Scholar · View at Scopus
  11. S. M. Prescott and F. A. Fitzpatrick, “Cyclooxygenase-2 and carcinogenesis,” Biochimica Biophysica Acta, vol. 1470, pp. 69–78, 2000. View at Google Scholar
  12. S. Chell, A. Kadi, A. C. Williams, and C. Paraskeva, “Mediators of PGE2 synthesis and signalling downstream of COX-2 represent potential targets for the prevention/treatment of colorectal cancer,” Biochimica et Biophysica Acta—Reviews on Cancer, vol. 1766, no. 1, pp. 104–119, 2006. View at Publisher · View at Google Scholar · View at Scopus
  13. S. Gately, “The contributions of cyclooxygenase-2 to tumor angiogenesis,” Cancer and Metastasis Reviews, vol. 19, no. 1-2, pp. 19–27, 2000. View at Publisher · View at Google Scholar · View at Scopus
  14. M. Tsujii, S. Kawano, S. Tsuji, H. Sawaoka, M. Hori, and R. N. DuBois, “Cyclooxygenase regulates angiogenesis induced by colon cancer cells,” Cell, vol. 29, no. 5, pp. 705–716, 1998. View at Publisher · View at Google Scholar · View at Scopus
  15. J. G. Rozic, C. Chakraborty, and P. K. Lala, “Cyclooxygenase inhibitors retard murine mammary tumor progression by reducing tumor cell migration, invasiveness and angiogenesis,” International Journal of Cancer, vol. 93, no. 4, pp. 497–506, 2001. View at Publisher · View at Google Scholar · View at Scopus
  16. M. Sonoshita, K. Takaku, N. Sasaki et al., “Acceleration of intestinal polyposis through prostaglandin receptor EP2 in ApcΔ716 knockout mice,” Nature Medicine, vol. 7, no. 9, pp. 1048–1051, 2001. View at Publisher · View at Google Scholar · View at Scopus
  17. L. Yang, N. Yamagata, R. Yadav et al., “Cancer-associated immunodefidency and dendritic cell abnormalities mediated by the prostaglandin EP2 receptor,” Journal of Clinical Investigation, vol. 111, no. 5, pp. 727–735, 2003. View at Publisher · View at Google Scholar · View at Scopus
  18. S. Kusmartsev and D. I. Gabrilovich, “Effect of tumor-derived cytokines and growth factors on differentiation and immune suppressive features of myeloid cells in cancer,” Cancer and Metastasis Reviews, vol. 25, no. 3, pp. 323–331, 2006. View at Publisher · View at Google Scholar · View at Scopus
  19. A. Pinzon-Charry, T. Maxwell, and J. A. López, “Dendritic cell dysfunction in cancer: a mechanism for immunosuppression,” Immunology and Cell Biology, vol. 83, no. 5, pp. 451–461, 2005. View at Publisher · View at Google Scholar · View at Scopus
  20. M. Mahic, S. Yaqub, C. C. Johansson, K. Taskén, and E. M. Aandahl, “FOXP3+CD4+CD25+ adaptive regulatory T cells express cyclooxygenase-2 and suppress effector T cells by a prostaglandin E2-dependent mechanism,” The Journal of Immunology, vol. 177, no. 1, pp. 246–254, 2006. View at Publisher · View at Google Scholar · View at Scopus
  21. D. S. Whittaker, K. S. Bahjat, L. L. Moldawer, and M. J. Clare-Salzler, “Autoregulation of human monocyte-derived dendritic cell maturation and IL-12 production by cyclooxygenase-2-mediated prostanoid production,” Journal of Immunology, vol. 165, no. 8, pp. 4298–4304, 2000. View at Publisher · View at Google Scholar · View at Scopus
  22. L. Minghetti, D. T. Walsh, G. Levi, and V. H. Perry, “In vivo expression of cyclooxygenase-2 in rat brain following intraparenchymal injection of bacterial endotoxin and inflammatory cytokines,” Journal of Neuropathology & Experimental Neurology, vol. 58, no. 11, pp. 1184–1191, 1999. View at Publisher · View at Google Scholar · View at Scopus
  23. R. Vlahos and A. G. Stewart, “Interleukin-1α and tumour necrosis factor-α modulate airway smooth muscle DNA synthesis by induction of cyclo-oxygenase-2: inhibition by dexamethasone and fluticasone propionate,” British Journal of Pharmacology, vol. 126, no. 6, pp. 1315–1324, 1999. View at Publisher · View at Google Scholar · View at Scopus
  24. Z.-F. Huang, J. B. Massey, and D. P. Via, “Differential regulation of cyclooxygenase-2 (COX-2) mRNA stability by interleukin-1β (IL-1β) and tumor necrosis factor-α (TNF-α) in human in vitro differentiated macrophages,” Biochemical Pharmacology, vol. 59, no. 2, pp. 187–194, 2000. View at Publisher · View at Google Scholar · View at Scopus
  25. H. Matsuura, M. Sakaue, K. Subbaramaiah et al., “Regulation of cyclooxygenase-2 by interferon γ and transforming growth factor α in normal human epidermal keratinocytes and squamous carcinoma cells. Role of mitogen-activated protein kinases,” Journal of Biological Chemistry, vol. 274, no. 41, pp. 29138–29148, 1999. View at Publisher · View at Google Scholar · View at Scopus
  26. H. Niiro, T. Otsuka, K. Izuhara et al., “Regulation by interleukin-10 and interleukin-4 of cyclooxygenase-2 expression in human neutrophils,” Blood, vol. 89, no. 5, pp. 1621–1628, 1997. View at Google Scholar · View at Scopus
  27. M. Díaz-Cazorla, D. Pérez-Sala, J. Ros, W. Jiménez, M. Fresno, and S. Lamas, “Regulation of cyclooxygenase-2 expression in human mesangial cells—transcriptional inhibition by IL-13,” European Journal of Biochemistry, vol. 260, no. 1, pp. 268–274, 1999. View at Publisher · View at Google Scholar · View at Scopus
  28. N. Alaaeddine, J. A. Di Battista, J. Pelletier, K. Kiansa, J. Cloutier, and J. Martel-Pelletier, “Inhibition of tumor necrosis factor α-induced prostaglandin E2 production by the antiinflammatory cytokines interleukin-4, interleukin-10, and interleukin-13 in osteoarthritic synovial fibroblasts: distinct targeting in the signaling pathways,” Arthritis & Rheumatism, vol. 42, no. 4, pp. 710–718, 1999. View at Publisher · View at Google Scholar
  29. H. Niiro, T. Otsuka, T. Tanabe et al., “Inhibition by interleukin-10 of inducible cyclooxygenase expression in lipopolysaccharide-stimulated monocytes: its underlying mechanism in comparison with interleukin-4,” Blood, vol. 85, no. 12, pp. 3736–3745, 1995. View at Google Scholar · View at Scopus
  30. T. Tanabe and N. Tohnai, “Cyclooxygenase isozymes and their gene structures and expression,” Prostaglandins & Other Lipid Mediators, vol. 68-69, pp. 95–114, 2002. View at Publisher · View at Google Scholar · View at Scopus
  31. E. M. Smyth, T. Grosser, M. Wang, Y. Yu, and G. A. FitzGerald, “Prostanoids in health and disease,” Journal of Lipid Research, vol. 50, pp. S423–S428, 2009. View at Publisher · View at Google Scholar · View at Scopus
  32. M. K. O'Banion, “Cyclooxygenase-2: molecular biology, pharmacology, and neurobiology,” Critical Reviews in Neurobiology, vol. 13, no. 1, pp. 45–82, 1999. View at Google Scholar · View at Scopus
  33. N. Zidar, K. Odar, D. Glavac, M. Jerse, T. Zupanc, and D. Stajer, “Cyclooxygenase in normal human tissues—is COX-1 really a constitutive isoform, and COX-2 an inducible isoform?” Journal of Cellular and Molecular Medicine, vol. 13, no. 9, pp. 3753–3763, 2009. View at Publisher · View at Google Scholar · View at Scopus
  34. T. Grosser, S. Fries, and G. A. FitzGerald, “Biological basis for the cardiovascular consequences of COX-2 inhibition: therapeutic challenges and opportunities,” Journal of Clinical Investigation, vol. 116, no. 1, pp. 4–15, 2006. View at Publisher · View at Google Scholar · View at Scopus
  35. D. A. Dixon, F. F. Blanco, A. Bruno, and P. Patrignani, “Mechanistic aspects of COX-2 expression in colorectal neoplasia,” Recent Results in Cancer Research, vol. 191, pp. 7–37, 2013. View at Publisher · View at Google Scholar · View at Scopus
  36. W. L. Smith and D. L. DeWitt, “Biochemistry of prostaglandin endoperoxide H synthase-1 and synthase-2 and their differential susceptibility to nonsteroidal anti-inflammatory drugs,” Seminars in Nephrology, vol. 15, no. 3, pp. 179–194, 1995. View at Google Scholar · View at Scopus
  37. R. N. DuBois, S. B. Abramson, L. Crofford et al., “Cyclooxygenase in biology and disease,” The FASEB Journal, vol. 12, no. 12, pp. 1063–1073, 1998. View at Google Scholar · View at Scopus
  38. R. M. Breyer, C. K. Bagdassarian, S. A. Myers, and M. D. Breyer, “Prostanoid receptors: subtypes and signaling,” Annual Review of Pharmacology and Toxicology, vol. 41, pp. 661–690, 2001. View at Publisher · View at Google Scholar · View at Scopus
  39. J. B. Regard, I. T. Sato, and S. R. Coughlin, “Anatomical profiling of G protein-coupled receptor expression,” Cell, vol. 135, no. 3, pp. 561–571, 2008. View at Publisher · View at Google Scholar · View at Scopus
  40. A. Alfranca, M. A. Iñiguez, M. Fresno, and J. M. Redondo, “Prostanoid signal transduction and gene expression in the endothelium: role in cardiovascular diseases,” Cardiovascular Research, vol. 70, no. 3, pp. 446–456, 2006. View at Publisher · View at Google Scholar · View at Scopus
  41. C. Rieser, G. Böck, H. Klocker, G. Bartsch, and M. Thurnher, “Prostaglandin E2 and tumor necrosis factor α cooperate to activate human dendritic cells: synergistic activation of interleukin 12 production,” Journal of Experimental Medicine, vol. 186, no. 9, pp. 1603–1608, 1997. View at Publisher · View at Google Scholar · View at Scopus
  42. T. Kambayashi, R. P. A. Wallin, and H.-G. Ljunggren, “cAMP-elevating agents suppress dendritic cell function,” Journal of Leukocyte Biology, vol. 70, no. 6, pp. 903–910, 2001. View at Google Scholar · View at Scopus
  43. K. Kabashima, D. Sakata, M. Nagamachi, Y. Miyachi, K. Inaba, and S. Narumiya, “Prostaglandin E2-EP4 signaling initiates skin immune responses by promoting migration and maturation of Langerhans cells,” Nature Medicine, vol. 9, no. 6, pp. 744–749, 2003. View at Google Scholar · View at Scopus
  44. C. Nataraj, D. W. Thomas, S. L. Tilley et al., “Receptors for prostaglandin E2 that regulate cellular immune responses in the mouse,” The Journal of Clinical Investigation, vol. 108, no. 8, pp. 1229–1235, 2001. View at Publisher · View at Google Scholar · View at Scopus
  45. E. Kuroda, T. Sugiura, K. Zeki, Y. Yoshida, and U. Yamashita, “Sensitivity difference to the suppressive effect of prostaglandin E2 among mouse strains: a possible mechanism to polarize Th2 type response in BALB/c mice,” Journal of Immunology, vol. 164, no. 5, pp. 2386–2395, 2000. View at Publisher · View at Google Scholar · View at Scopus
  46. S. W. Russell and J. L. Pace, “Both the kind and magnitude of stimulus are important in overcoming the negative regulation of macrophage activation by PGE2,” Journal of Leukocyte Biology, vol. 35, no. 3, pp. 291–301, 1984. View at Google Scholar · View at Scopus
  47. H. Harizi, M. Juzan, C. Grosset, M. Rashedi, and N. Gualde, “Dendritic cells issued in vitro from bone marrow produce PGE2 that contributes to the immunomodulation induced by antigen-presenting cells,” Cellular Immunology, vol. 209, no. 1, pp. 19–28, 2001. View at Publisher · View at Google Scholar · View at Scopus
  48. Y. Sugimoto, S. Narumiya, and A. Ichikawa, “Distribution and function of prostanoid receptors: studies from knockout mice,” Progress in Lipid Research, vol. 39, no. 4, pp. 289–314, 2000. View at Publisher · View at Google Scholar · View at Scopus
  49. A. D. Goldberg, C. D. Allis, and E. Bernstein, “Epigenetics: a lands cape takes shape,” Cell, vol. 128, no. 4, pp. 635–638, 2007. View at Publisher · View at Google Scholar · View at Scopus
  50. M. Esteller, “Cancer epigenomics: DNA methylomes and histone-modification maps,” Nature Reviews Genetics, vol. 8, no. 4, pp. 286–298, 2007. View at Publisher · View at Google Scholar · View at Scopus
  51. S. L. Berger, “The complex language of chromatin regulation during transcription,” Nature, vol. 447, no. 7143, pp. 407–412, 2007. View at Publisher · View at Google Scholar · View at Scopus
  52. A. P. Wolffe and M. A. Matzke, “Epigenetics: regulation through repression,” Science, vol. 286, no. 5439, pp. 481–486, 1999. View at Publisher · View at Google Scholar · View at Scopus
  53. T. Jenuwein and C. D. Allis, “Translating the histone code,” Science, vol. 293, no. 5532, pp. 1074–1080, 2001. View at Publisher · View at Google Scholar · View at Scopus
  54. G. Egger, G. Liang, A. Aparicio, and P. A. Jones, “Epigenetics in human disease and prospects for epigenetic therapy,” Nature, vol. 429, no. 6990, pp. 457–463, 2004. View at Publisher · View at Google Scholar · View at Scopus
  55. R. Z. Jurkowska, T. P. Jurkowski, and A. Jeltsch, “Structure and function of mammalian DNA methyltransferases,” ChemBioChem, vol. 12, no. 2, pp. 206–222, 2011. View at Publisher · View at Google Scholar · View at Scopus
  56. R. D. Hotchkiss, “The quantitative separation of purines, pyrimidines, and nucleosides by paper chromatography,” The Journal of Biological Chemistry, vol. 175, pp. 315–332, 1948. View at Google Scholar
  57. B. Richardson, “Impact of aging on DNA methylation,” Ageing Research Reviews, vol. 2, no. 3, pp. 245–261, 2003. View at Publisher · View at Google Scholar · View at Scopus
  58. S. Klimasauskas, S. Kumar, R. J. Roberts, and X. Cheng, “Hhal methyltransferase flips its target base out of the DNA helix,” Cell, vol. 76, no. 2, pp. 357–369, 1994. View at Publisher · View at Google Scholar · View at Scopus
  59. E. Hodges, A. Molaro, C. O. Dos Santos et al., “Directional DNA methylation changes and complex intermediate states accompany lineage specificity in the adult hematopoietic compartment,” Molecular Cell, vol. 44, no. 1, pp. 17–28, 2011. View at Publisher · View at Google Scholar · View at Scopus
  60. R. Lister, M. Pelizzola, R. H. Dowen et al., “Human DNA methylomes at base resolution show widespread epigenomic differences,” Nature, vol. 462, no. 7271, pp. 315–322, 2009. View at Publisher · View at Google Scholar · View at Scopus
  61. H. Harizi, M. Juzan, V. Pitard, J.-F. Moreau, and N. Gualde, “Cyclooxygenase-2-issued prostaglandin E2 enhances the production of endogenous IL-10, which down-regulates dendritic cell functions,” Journal of Immunology, vol. 168, no. 5, pp. 2255–2263, 2002. View at Publisher · View at Google Scholar · View at Scopus
  62. R. E. Harris, “Cyclooxygenase-2 (cox-2) blockade in the chemoprevention of cancers of the colon, breast, prostate, and lung,” Inflammopharmacology, vol. 17, no. 2, pp. 55–67, 2009. View at Publisher · View at Google Scholar · View at Scopus
  63. I. Cebola and M. A. Peinado, “Epigenetic deregulation of the COX pathway in cancer,” Progress in Lipid Research, vol. 51, no. 4, pp. 301–313, 2012. View at Publisher · View at Google Scholar · View at Scopus
  64. M. Sahin, E. Sahin, and S. Koksoy, “Regulatory T cells in cancer: an overview and perspectives on Cyclooxygenase-2 and Foxp3 DNA methylation,” Human Immunology, vol. 74, no. 9, pp. 1061–1068, 2013. View at Publisher · View at Google Scholar · View at Scopus
  65. B. G. Cosío, B. Mann, K. Ito et al., “Histone acetylase and deacetylase activity in alveolar macrophages and blood mononocytes in asthma,” American Journal of Respiratory and Critical Care Medicine, vol. 170, no. 2, pp. 141–147, 2004. View at Publisher · View at Google Scholar · View at Scopus
  66. K. Ito, G. Caramori, S. Lim et al., “Expression and activity of histone deacetylases in human asthmatic airways,” The American Journal of Respiratory and Critical Care Medicine, vol. 166, no. 3, pp. 392–396, 2002. View at Publisher · View at Google Scholar · View at Scopus
  67. P. J. Barnes, I. M. Adcock, and K. Ito, “Histone acetylation and deacetylation: importance in inflammatory lung diseases,” European Respiratory Journal, vol. 25, no. 3, pp. 552–563, 2005. View at Publisher · View at Google Scholar · View at Scopus
  68. F. Yeung, J. E. Hoberg, C. S. Ramsey et al., “Modulation of NF-κB-dependent transcription and cell survival by the SIRT1 deacetylase,” The EMBO Journal, vol. 23, no. 12, pp. 2369–2380, 2004. View at Publisher · View at Google Scholar · View at Scopus
  69. C.-H. Kuo, Y.-C. Ko, S.-N. Yang et al., “Effects of PGI2 analogues on Th1- and Th2-related chemokines in monocytes via epigenetic regulation,” Journal of Molecular Medicine, vol. 89, no. 1, pp. 29–41, 2011. View at Publisher · View at Google Scholar · View at Scopus
  70. C. H. Kuo, C. H. Lin, S. N. Yang et al., “Effect of prostaglandin I2 analogs on cytokine expression in human myeloid dendritic cells via epigenetic regulation,” Molecular Medicine, vol. 18, no. 1, pp. 433–444, 2012. View at Google Scholar · View at Scopus
  71. S. Sakaguchi, M. Ono, R. Setoguchi et al., “Foxp3+CD25+CD4+ natural regulatory T cells in dominant self-tolerance and autoimmune disease,” Immunological Reviews, vol. 212, pp. 8–27, 2006. View at Publisher · View at Google Scholar · View at Scopus
  72. W. Zou, “Regulatory T cells, tumour immunity and immunotherapy,” Nature Reviews Immunology, vol. 6, no. 4, pp. 295–307, 2006. View at Publisher · View at Google Scholar · View at Scopus
  73. F. Baratelli, Y. Lin, L. Zhu et al., “Prostaglandin E2 induces FOXP3 gene expression and T regulatory cell function in human CD4+ T cells,” The Journal of Immunology, vol. 175, no. 3, pp. 1483–1490, 2005. View at Publisher · View at Google Scholar · View at Scopus
  74. S. Yaqub, K. Henjum, M. Mahic et al., “Regulatory T cells in colorectal cancer patients suppress anti-tumor immune activity in a COX-2 dependent manner,” Cancer Immunology, Immunotherapy, vol. 57, no. 6, pp. 813–821, 2008. View at Publisher · View at Google Scholar · View at Scopus
  75. M. Huang, S. Sharma, J. T. Mao, and S. M. Dubinett, “Non-small cell lung cancer-derived soluble mediators and prostaglandin E2 enhance peripheral blood lymphocyte IL-10 transcription and protein production,” The Journal of Immunology, vol. 157, no. 12, pp. 5512–5520, 1996. View at Google Scholar · View at Scopus
  76. M. Stolina, S. Sharma, Y. Lin et al., “Specific inhibition of cyclooxygenase 2 restores antitumor reactivity by altering the balance of IL-10 and IL-12 synthesis,” Journal of Immunology, vol. 164, no. 1, pp. 361–370, 2000. View at Publisher · View at Google Scholar · View at Scopus
  77. S. Sharma, M. Stolina, S.-C. Yang et al., “Tumor cyclooxygenase 2-dependent suppression of dendritic cell function,” Clinical Cancer Research, vol. 9, no. 3, pp. 961–968, 2003. View at Google Scholar · View at Scopus
  78. S. Sharma, S.-C. Yang, L. Zhu et al., “Tumor cyclooxygenase-2/prostaglandin E2-dependent promotion of FOXP3 expression and CD4+CD25+ T regulatory cell activities in lung cancer,” Cancer Research, vol. 65, no. 12, pp. 5211–5220, 2005. View at Publisher · View at Google Scholar · View at Scopus
  79. J. D. Fontenot, M. A. Gavin, and A. Y. Rudensky, “Foxp3 programs the development and function of CD4+CD25+ regulatory T cells,” Nature Immunology, vol. 4, no. 4, pp. 330–336, 2003. View at Publisher · View at Google Scholar · View at Scopus
  80. S. Hori, T. Nomura, and S. Sakaguchi, “Control of regulatory T cell development by the transcription factor Foxp3,” Science, vol. 299, no. 5609, pp. 1057–1061, 2003. View at Publisher · View at Google Scholar · View at Scopus
  81. X.-L. Yuan, L. Chen, M.-X. Li et al., “Elevated expression of Foxp3 in tumor-infiltrating Treg cells suppresses T-cell proliferation and contributes to gastric cancer progression in a COX-2-dependent manner,” Clinical Immunology, vol. 134, no. 3, pp. 277–288, 2010. View at Publisher · View at Google Scholar · View at Scopus
  82. M. Tsujii and R. N. DuBois, “Alterations in cellular adhesion and apoptosis in epithelial cells overexpressing prostaglandin endoperoxide synthase 2,” Cell, vol. 83, no. 3, pp. 493–501, 1995. View at Publisher · View at Google Scholar · View at Scopus
  83. M. S. Simper, J. E. Rundhaug, C. Mikulec et al., “The tumor promoting activity of the EP4 receptor for prostaglandin E2 in murine skin,” Molecular Oncology, vol. 8, no. 8, pp. 1626–1639, 2014. View at Publisher · View at Google Scholar
  84. A. M. Algra and P. M. Rothwell, “Effects of regular aspirin on long-term cancer incidence and metastasis: a systematic comparison of evidence from observational studies versus randomised trials,” The Lancet Oncology, vol. 13, no. 5, pp. 518–527, 2012. View at Publisher · View at Google Scholar · View at Scopus
  85. M. J. Thun, E. J. Jacobs, and C. Patrono, “The role of aspirin in cancer prevention,” Nature Reviews Clinical Oncology, vol. 9, no. 5, pp. 259–267, 2012. View at Publisher · View at Google Scholar · View at Scopus
  86. X. Liao, P. Lochhead, R. Nishihara et al., “Aspirin use, tumor PIK3CA mutation, and colorectal-cancer survival,” The New England Journal of Medicine, vol. 367, no. 17, pp. 1596–1606, 2012. View at Publisher · View at Google Scholar · View at Scopus
  87. J. Huang, C. Plass, and C. Gerhäuser, “Cancer chemoprevention by targeting the epigenome,” Current Drug Targets, vol. 12, no. 13, pp. 1925–1956, 2011. View at Publisher · View at Google Scholar · View at Scopus
  88. E. Yiannakopoulou, “Targeting epigenetic mechanisms and microRNAs by aspirin and other non steroidal anti-inflammatory agents—implications for cancer treatment and chemoprevention,” Cellular Oncology, vol. 37, no. 3, pp. 167–178, 2014. View at Publisher · View at Google Scholar
  89. E. Okuda-Ashitaka, K. Sakamoto, T. Ezashi, K. Miwa, S. Ito, and O. Hayaishi, “Suppression of prostaglandin E receptor signaling by the variant form of EP1 subtype,” The Journal of Biological Chemistry, vol. 271, no. 49, pp. 31255–31261, 1996. View at Publisher · View at Google Scholar · View at Scopus
  90. M. Toyota, L. Shen, M. Ohe-Toyota, S. R. Hamilton, F. A. Sinicrope, and J.-P. J. Issa, “Aberrant methylation of the cyclooxygenase 2 CpG island in colorectal tumors,” Cancer Research, vol. 60, no. 15, pp. 4044–4048, 2000. View at Google Scholar · View at Scopus
  91. E. R. Greene, S. Huang, C. N. Serhan, and D. Panigrahy, “Regulation of inflammation in cancer by eicosanoids,” Prostaglandins and Other Lipid Mediators, vol. 96, pp. 27–36, 2011. View at Publisher · View at Google Scholar · View at Scopus
  92. D. Wang and R. N. Dubois, “Eicosanoids and cancer,” Nature Reviews Cancer, vol. 10, no. 3, pp. 181–193, 2010. View at Publisher · View at Google Scholar · View at Scopus
  93. D. G. Menter, R. L. Schilsky, and R. N. DuBois, “Cyclooxygenase-2 and cancer treatment: understanding the risk should be worth the reward,” Clinical Cancer Research, vol. 16, no. 5, pp. 1384–1390, 2010. View at Publisher · View at Google Scholar · View at Scopus
  94. H.-S. Jong, H. Inoue, T. Tanabe, and Y.-J. Bang, “Transcriptional silencing of cyclooxygenase-2 by hyper-methylation of the 5′ CpG island in human gastric carcinoma cells,” Cancer Research, vol. 61, no. 11, pp. 4628–4635, 2001. View at Google Scholar · View at Scopus
  95. T. Kikuchi, F. Itoh, M. Toyota et al., “Aberrant methylation and histone deacetylation of cyclooxygenase 2 in gastric cancer,” International Journal of Cancer, vol. 97, no. 3, pp. 272–277, 2002. View at Publisher · View at Google Scholar · View at Scopus
  96. N. Omura, M. Griffith, A. Vincent et al., “Cyclooxygenase-deficient pancreatic cancer cells use exogenous sources of prostaglandins,” Molecular Cancer Research, vol. 8, no. 6, pp. 821–832, 2010. View at Publisher · View at Google Scholar · View at Scopus
  97. X. Ma, Q. Yang, K. T. Wilson, N. Kundu, S. J. Meltzer, and A. M. Fulton, “Promoter methylation regulates cyclooxygenase expression in breast cancer,” Breast Cancer Research, vol. 6, no. 4, pp. R316–R321, 2004. View at Publisher · View at Google Scholar · View at Scopus
  98. L. W. C. Chow, L. Zhu, W. T. Y. Loo, and E. L. H. Lui, “Aberrant methylation of cyclooxygenase-2 in breast cancer patients,” Biomedicine and Pharmacotherapy, vol. 59, no. 2, pp. S264–S267, 2005. View at Publisher · View at Google Scholar · View at Scopus
  99. H. Murata, S. Tsuji, M. Tsujii et al., “Promoter hypermethylation silences cyclooxygenase-2 (Cox-2) and regulates growth of human hepatocellular carcinoma cells,” Laboratory Investigation, vol. 84, no. 8, pp. 1050–1059, 2004. View at Publisher · View at Google Scholar · View at Scopus
  100. N. Nishida, T. Nagasaka, T. Nishimura, I. Ikai, C. R. Boland, and A. Goel, “Aberrant methylation of multiple tumor suppressor genes in aging liver, chronic hepatitis, and hepatocellular carcinoma,” Hepatology, vol. 47, no. 3, pp. 908–918, 2008. View at Publisher · View at Google Scholar · View at Scopus
  101. T.-H. Um, H. Kim, B.-K. Oh et al., “Aberrant CpG island hypermethylation in dysplastic nodules and early HCC of hepatitis B virus-related human multistep hepatocarcinogenesis,” Journal of Hepatology, vol. 54, no. 5, pp. 939–947, 2011. View at Publisher · View at Google Scholar · View at Scopus
  102. R. Soo, T. Putti, Q. Tao et al., “Overexpression of cyclooxygenase-2 in nasopharyngeal carcinoma and association with epidermal growth factor receptor expression,” Archives of Otolaryngology—Head and Neck Surgery, vol. 131, no. 2, pp. 147–152, 2005. View at Publisher · View at Google Scholar · View at Scopus
  103. D. Lodygin, A. Epanchintsev, A. Menssen, J. Diebold, and H. Hermeking, “Functional epigenomics identifies genes frequently silenced in prostate cancer,” Cancer Research, vol. 65, no. 10, pp. 4218–4227, 2005. View at Publisher · View at Google Scholar · View at Scopus
  104. P. J. Bastian, J. Ellinger, L. C. Heukamp, P. Kahl, S. C. Müller, and A. von Rücker, “Prognostic value of CpG island hypermethylation at PTGS2, RAR-beta, EDNRB, and other gene loci in patients undergoing radical prostatectomy,” European Urology, vol. 51, no. 3, pp. 665–674, 2007. View at Publisher · View at Google Scholar · View at Scopus
  105. S. P. Dawsey, M. J. Roth, L. Adams et al., “COX-2 (PTGS2) gene methylation in epithelial, subepithelial lymphocyte and stromal tissue compartments in a spectrum of esophageal squamous neoplasia,” Cancer Detection and Prevention, vol. 32, no. 2, pp. 135–139, 2008. View at Publisher · View at Google Scholar · View at Scopus
  106. X. Y. Meng, S. T. Zhu, Y. Zong, Y. J. Wang, P. Li, and S. T. Zhang, “Promoter hypermethylation of cyclooxygenase-2 gene in esophageal squamous cell carcinoma,” Diseases of the Esophagus, vol. 24, no. 6, pp. 444–449, 2011. View at Publisher · View at Google Scholar · View at Scopus
  107. S. Kulkarni, J. S. Rader, F. Zhang et al., “Cyclooxygenase-2 is overexpressed in human cervical cancer,” Clinical Cancer Research, vol. 7, no. 2, pp. 429–434, 2001. View at Google Scholar · View at Scopus
  108. K. Subbaramaiah and A. J. Dannenberg, “Cyclooxygenase-2 transcription is regulated by human papillomavirus 16 E6 and E7 oncoproteins: evidence of a corepressor/coactivator exchange,” Cancer Research, vol. 67, no. 8, pp. 3976–3985, 2007. View at Publisher · View at Google Scholar · View at Scopus
  109. I. Venza, M. Visalli, C. Fortunato et al., “PGE2 induces interleukin-8 derepression in human astrocytoma through coordinated DNA demethylation and histone hyperacetylation,” Epigenetics, vol. 7, no. 11, pp. 1315–1330, 2012. View at Publisher · View at Google Scholar · View at Scopus
  110. Y. Sugimoto and S. Narumiya, “Prostaglandin E receptors,” The Journal of Biological Chemistry, vol. 282, no. 16, pp. 11613–11617, 2007. View at Publisher · View at Google Scholar · View at Scopus
  111. K. Gomi, F. G. Zhu, and J. S. Marshall, “Prostaglandin E2 selectively enhances the IgE-mediated production of IL-6 and granulocyte-macrophage colony-stimulating factor by mast cells through an EP1/EP3-dependent mechanism,” The Journal of Immunology, vol. 165, no. 11, pp. 6545–6552, 2000. View at Publisher · View at Google Scholar · View at Scopus
  112. Y. Shoji, M. Takahashi, T. Kitamura et al., “Downregulation of prostaglandin E receptor subtype EP3 during colon cancer development,” Gut, vol. 53, no. 8, pp. 1151–1158, 2004. View at Publisher · View at Google Scholar · View at Scopus
  113. S. G. Gray, N. Al-Sarraf, A.-M. Baird, M.-C. Cathcart, E. McGovern, and K. J. O'Byrne, “Regulation of EP receptors in non-small cell lung cancer by epigenetic modifications,” European Journal of Cancer, vol. 45, no. 17, pp. 3087–3097, 2009. View at Publisher · View at Google Scholar · View at Scopus
  114. A. M. Fulton, X. Ma, and N. Kundu, “Targeting prostaglandin E EP receptors to inhibit metastasis,” Cancer Research, vol. 66, no. 20, pp. 9794–9797, 2006. View at Publisher · View at Google Scholar · View at Scopus
  115. D. S. Shames, L. Girard, B. Gao et al., “A genome-wide screen for promoter methylation in lung cancer identifies novel methylation markers for multiple malignancies,” PLoS Medicine, vol. 3, article e486, 2006. View at Publisher · View at Google Scholar · View at Scopus
  116. K. Krysan, K. L. Reckamp, H. Dalwadi et al., “Prostaglandin E2 activates mitogen-activated protein kinase/Erk pathway signaling and cell proliferation in non-small cell lung cancer cells in an epidermal growth factor receptor-independent manner,” Cancer Research, vol. 65, no. 14, pp. 6275–6281, 2005. View at Publisher · View at Google Scholar · View at Scopus
  117. Y. Sugino, A. Misawa, J. Inoue et al., “Epigenetic silencing of prostaglandin E receptor 2 (PTGER2) is associated with progression of neuroblastomas,” Oncogene, vol. 26, no. 53, pp. 7401–7413, 2007. View at Publisher · View at Google Scholar · View at Scopus
  118. J. Chen, C. Röcken, L. Klein-Hitpass et al., “Microarray analysis of gene expression in metastatic gastric cancer cells after incubation with the methylation inhibitor 5-aza-2′-deoxycytidine,” Clinical & experimental metastasis, vol. 21, no. 5, pp. 389–397, 2004. View at Publisher · View at Google Scholar · View at Scopus
  119. L. Tian, M. Suzuki, T. Nakajima et al., “Clinical significance of aberrant methylation of prostaglandin E receptor 2 (PTGER2) in nonsmall cell lung cancer association with prognosis, PTGER2 expression, and epidermal growth factor receptor mutation,” Cancer, vol. 113, no. 6, pp. 1396–1403, 2008. View at Publisher · View at Google Scholar · View at Scopus
  120. S. K. Huang, A. S. Fisher, A. M. Scruggs et al., “Hypermethylation of PTGER2 confers prostaglandin E2 resistance in fibrotic fibroblasts from humans and mice,” The American Journal of Pathology, vol. 177, no. 5, pp. 2245–2255, 2010. View at Publisher · View at Google Scholar · View at Scopus
  121. E. Piazuelo, P. Jiménez, M. Strunk et al., “Effects of selective PGE2 receptor antagonists in esophageal adenocarcinoma cells derived from Barrett's esophagus,” Prostaglandins and Other Lipid Mediators, vol. 81, no. 3-4, pp. 150–161, 2006. View at Publisher · View at Google Scholar · View at Scopus